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Abstract
Background: The caregivers of people who experience psychosis are themselves at risk of developing physical and
mental health problems. This risk is increased for older adult caregivers who also have to manage the lifestyle and
health changes associated with ageing. As a consequence, older adult caregivers are in particular need of support;
we propose a Written Emotional Disclosure (WED) intervention, called Positive Written Disclosure (PWD).
Methods/design: This is a pilot randomised controlled trial of PWD compared to a neutral writing control and a no
writing condition. We aim to recruit 60 participants, 20 in each arm. This study will utilise a mixed-methods
approach and collect quantitative (questionnaires) and qualitative (interviews) data. Quantitative data will be
collected at baseline and 1, 3, and 6 months post baseline. Participants who complete a writing task (PWD or
neutral writing control) will be invited to complete an exit interview to discuss their experiences of the intervention
and study. The study is supported by a patient and public involvement group.
Discussion: The results of this trial will determine whether a definitive trial is justified. If so, the quantitative and
qualitative findings will be used to refine the intervention and study protocols.
Trial registration: ISRCTN, ISRCTN79116352. Registered on 23 January 2017
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Background
Many people who experience psychosis require occa-
sional or regular support from family or friends to
complete their activities of daily living, and for some,
this support is needed on a longer-term basis [1]. The
family and friends that provide this support are generally
referred to by clinical services as caregivers [2]. The role
of these caregivers is vital for both the care recipient and
society as a whole. Caregivers of people with psychosis
spend on average 5.6 h a day providing care—this
equates to more hours per week than a full-time job [3].
In the UK, it would cost the National Health Service
(NHS) £34,000 per annum to hire a support worker to
provide the same amount of care [3].
Being a caregiver for someone experiencing psychosis
can be physically, mentally, and emotionally demanding.
These caregivers are at risk of developing a number of
health problems, such as exhaustion [4], anxiety and de-
pression [5], and posttraumatic stress disorder (PTSD)
[6]. Many caregivers find it difficult to engage in leisure
or social activities and maintain any form of paid em-
ployment [7]. For older caregivers, this risk is increased
further as they have to manage their own age-related
health difficulties alongside the challenges of caregiving
[8, 9]. Despite these needs, healthcare services consistently
fail to consider or provide support for caregivers [10].
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The UK’s National Institute for Health and Care Excel-
lence (NICE) [11] guidelines recommend that family
therapy should be offered to everyone with psychosis
and their families. Unfortunately, family medicine imple-
mentation rates continue to be poor [1, 12] due to lim-
ited resources and lack of service funding [13]. Instead,
some clinical and third sector organisations offer care-
givers support groups. While some caregivers report
benefits from attending these groups, they do not suit
others and the dropout rates tend to be high [14]. Care-
givers report finding it difficult to make the time to at-
tend (because of caregiving duties) and feeling
uncomfortable talking in a group [15]. Alternative ap-
proaches to improve the wellbeing of caregivers need to
be considered—particularly the ones that do not require
significant clinical resources and are both acceptable and
accessible for caregivers.
One possible intervention that could be helpful for
these caregivers is Written Emotional Disclosure
(WED). WED is a self-directed writing therapy that
typically involves writing about a stressful or trau-
matic experience continuously for 20 min each time,
for three consecutive days [16]. Multiple meta-
analyses have demonstrated WED to be effective on a
range of outcomes in both clinical and nonclinical
samples [17–20], including small beneficial effects for
caregivers generally [21]. However, very limited bene-
fits have been found in trials of WED for caregivers
of people with psychosis [22, 23].
An alternative form of therapeutic writing, called
Positive Written Disclosure (PWD), has recently been
evaluated in the research setting. PWD follows an
identical format to WED, but the instructions ask
participants to write about positive, rather than trau-
matic, experiences. A recent large, three-arm trial
(comparing PWD to WED and a writing control task)
showed that for some caregivers, PWD led to decreased
anxiety and depression post-intervention and subsequent
follow-up, whereas the caregivers undertaking WED expe-
rienced no improvements [24]. Although these findings
are promising, they cannot automatically be extrapolated
to caregivers supporting people with psychosis because
of the unique and additional challenges—including
the stigma of mental health problems and its impact
on the wellbeing of the caregiver and their care re-
cipient [25].
The long-term aim of this research program is to
explore the effects of PWD for older adult caregivers
of people with psychosis. The first step in this research
program is to conduct a pilot feasibility randomised
controlled trial.
The aims of the pilot trial are to (1) determine
whether a definitive trial of PWD on older adult care-
givers of people experiencing psychosis is justified in
terms of recruitment, retention, reasons for dropout,
and adherence to writing task; (2) estimate the
pooled standard deviation for the primary outcome
(mood) to be used for future sample size calcula-
tions in the event of a definitive trial being justified
and gain insight into what an appropriate Minimal
Clinically Important Difference (MCID) might be for
future studies; and (3) identify whether PWD and
the study design is acceptable, accessible, and
feasible to participants by using a combination of
questionnaires, recruitment and retention rates
(quantitative), and post-study interviews (qualitative),
all supported by a patient and public involvement
reference group.
Methods/design
This study is a single blind, external pilot randomised
controlled trial (RCT) with three parallel arms: (1)
Positive Written Disclosure (PWD), (2) Writing Con-
trol task (WC), and (3) Non-Writing Control group
(NWC). Prior to recruitment, an independent statisti-
cian will generate a randomised group allocation se-
quence, allocating each participant ID to one of the
three arms. The randomisation will use a 1:1:1 ratio
block randomisation to create a randomly permuted
sequence; this sequence will be concealed from the
research team. The group allocation will be concealed
from participants until they have completed their
baseline assessment; after the baseline assessment,
participants will receive an opaque, sealed envelope
that contains their group allocation. The trial research
assistants will remain blinded to participants’ group
allocations throughout the study.
We will collect the quantitative outcome data at
baseline (T0—prior to participants being informed of
their group allocation) and 1 (T1), 3 (T2), and 6
(T3) months post baseline. Participants will provide
consent and complete the baseline assessment with a
research assistant. Participants randomised to complete a
writing task (either PWD or WC) will be asked to
complete the writing task within a week of completing
the T0 assessment. They will be asked to return their
writing packs to the research team when they
complete the T1 assessment. Participants will be able
to request their writing back at the end of the study.
All participants who are allocated to either the PWD
or WC groups will also be invited to complete an exit
interview after completing the 6-month assessment.
See Fig. 1 for CONSORT diagram.
Carers of people with psychosis have been involved in
each part of the research process. Their feedback has
helped to shape this research study from its conception,
through to design and delivery (see “Public and patient
involvement” section for more information).
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Participants
Participants will be recruited using a number of routes,
including via NHS services and third sector organisa-
tions. Mental health practitioners working in NHS sec-
ondary mental health services will be asked to identify
the caregivers of anyone on their current case load ex-
periencing psychosis who may be interested in this
study. Also, local general practitioners (GP) will be asked
to screen their carers register and patient records to
identify any potential participants who meet the study
criteria. Invitations will also be sent to any caregivers
listed on our database of people who have consented to
being contacted about research studies, and the research
team will publicise the study through relevant local third
sector organisations. We will be accepting both practi-
tioner- and self-referrals. We plan to recruit a total of 60
participants (20 in each arm). This recruitment target is
in line with the recommendations of Julious [26] that a
minimum of 12 participants per arm is an appropriate
sample size for pilot trials. Recruiting 20 participants per
arm allows for a potential attrition rate of up to 40%.
The study will use the following inclusion criteria: par-
ticipants must (1) be classified as a primary caregiver, as
defined by the Royal College of General Practitioners
and The Princess Royal Trust for Carers [2] (this in-
cludes “any person who provides unpaid support to a
partner, child, relative or friend who couldn’t manage to
live independently or whose health or wellbeing would
deteriorate without this help” (p. 9)); (2) aged 60 years
or over; (3) provide care for someone experiencing
psychosis (this includes persons with a diagnosis of
schizophrenia, schizoaffective disorder, schizotypal per-
sonality disorder, delusional disorder, psychosis not
otherwise specified, bipolar, and depression with psych-
otic features); and (4) be able to read and write in Eng-
lish. Participants will be excluded if they are currently
Fig. 1 The C4C Study CONSORT. Note: PWD Positive Written Disclosure, WC Writing Control task, NWC Non-Writing Control group
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receiving psychological therapy, including family ther-
apy, or if such therapy is scheduled to start in the next
6 months.
Positive Written Disclosure (PWD)
The PWD intervention protocol will broadly follow the
original Pennebaker and Beall [27] protocol, with the ex-
ception of the writing topic. Participants will be asked to
write about a positive and happy experience they have
had, continuously for 20 min, for three consecutive days.
Participants will be given instructions prior to beginning
their writing that will encourage them to “really let go
and explore your very deepest emotions and thoughts”.
Within these instructions there will be several prompts
as to the kinds of experiences that they may like to write
about; for example “You might link your writing to your
future and who you would like to become, to who you
were in the past, or to who you are now. Perhaps from
being in love or being a parent, from personal achieve-
ments at work or in a hobby, or from listening to music
or suddenly “being hit” by a book or painting. These are
only suggestions however – you may write about any
positive and happy experience(s) you like.”
Participants will also be advised that spelling and
grammar are not important and that if they run out of
things to write before the 20 min has ended, they should
repeat what they have already written. The writing can
be completed at a time and place that is convenient for
the participant. It is hypothesised that by setting aside
some time to concentrate on a positive experience, and
embody positive emotions, this will improve the care-
givers’ wellbeing and mood.
Control conditions
Writing Control task (WC)
In previous trials of PWD, and WED more generally,
participants allocated to the Writing Control task are
often asked to write about time management [28], as this
is assumed to be a neutral topic. However, in a previous
pilot trial with caregivers, this control condition was
found to be inappropriate because most caregivers spent
a significant amount of their time caring, so it tends to
be an emotionally charged topic [23]. An alternative
writing control task has been developed for use with
caregivers, whereby caregivers were asked to objectively
describe images of outdoor scenes [24]. However, our
Caring for Caregivers (C4C) Lived Experience Advisory
Panel (LEAP) of caregivers felt that writing about an
image of outdoor scenes was not neutral—as it could ei-
ther improve mood because the image is aesthetically
pleasing or it could worsen mood because many care-
givers are unable to visit such places due to the demands
of their caregiving responsibilities. Being attentive to this
feedback, we have selected, with the help of our C4C
LEAP, a set of images that are primarily used within
change detection research; the images depict different
rooms within a house [29]. These images not only were
considered to be both neutral but also have sufficient de-
tail to keep participants engaged enough to write about
them for 20 min.
Participants will be asked to write about one image
during each writing session; they will be asked to write
continuously for 20 min on each of three consecutive
days (the same duration as the PWD group). The writing
instructions will prompt participants to avoid including
any emotions in their writing, i.e. “Please do not add
personal information or give your opinions on the im-
ages. Please try to be as objective and detailed as pos-
sible.” Similar to the PWD group, participants in this
group will be informed not to worry about spelling or
grammar and that they can complete the writing when
and where is most convenient for them. If they run out
of things to write before the 20 min is up, they will be
instructed to repeat what they have already written.
Non-Writing Control group (NWC)
The participants who are allocated to the NWC condi-
tion will not be asked to complete any writing—these
participants will be asked to continue with their daily ac-
tivities as usual. The inclusion of the NWC is based
upon feedback from the C4C LEAP that having permis-
sion to take time out of your day to write, regardless of
the topic, may be beneficial. The inclusion of the NWC
group will allow us to determine whether it is the act of
writing or the topic being written about that produces
benefits (if any).
Measures
This study will assess the use the Positive and Negative
Affect Scale (PANAS) [30] as the primary outcome for
the main trial. The PANAS is made up on 20 items—10
measuring positive emotion and 10 measuring negative
emotion. The positive and negative emotion scales will
be analysed separately and treated as co-primary out-
comes. Each item asks participants to rate the extent to
which they have felt this emotion over the previous week
on a 5-point Likert scale (from very slightly or not at all,
to extremely). The PANAS has strong internal
consistency (Cronbach’s α > .84) [30]. We will also meas-
ure the following potential secondary outcomes:
(1)The Depression Anxiety and Stress Scale (DASS-21)
[31] measures symptoms of depression, anxiety, and
stress in both clinical and nonclinical samples over
the past week. Each scale is comprised of seven
items. The measure has strong internal consistency
(Cronbach’s α = .88) [32].
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(2)Caregiver Wellbeing and Support Scale (CWSv2)
[33] is a measure of wellbeing, over the past
4 weeks, that is specific to caregivers. The
questionnaire was commissioned by the National
Institute for Health Research (NIHR) Service
Delivery and Organisation (SDO) program. It is
made up of 32 items and has strong internal
consistency (Cronbach’s α = .96) [33].
(3)General Self-Efficacy Scale (GSES) [34] has one scale
made up of 10 items. The questionnaire measures
global self-efficacy over the past week, i.e. not in re-
lation to any specific domain. The GSES has strong
internal consistency (Cronbach’s α > .86) [35].
(4)Leisure Time Satisfaction (LTS) measure [36] was
developed specifically for caregivers to measure their
engagement in pleasurable activities outside of their
caring responsibilities over the past month. The
scale is made up of 6 items and has strong internal
consistency (Cronbach’s α = .94) [37].
(5)Measures of overall mood will be collected both pre-
and post-writing for each day of writing. Mood will
be measured using a visual analogue scale (VAS)
ranging from feeling very negative (1) to very posi-
tive (10).
We will also collect data on the Toronto Alexithymia
Scale (TAS 20) [38]. This questionnaire measures trait
alexithymia (the ability to identify emotions). As alex-
ithymia is considered a trait characteristic, we will only
administer this measure at baseline (T0). The question-
naire has three sub-scales: difficulty describing feelings,
difficulty identifying feelings, and externally orientated
thinking. These sub-scales are comprised of five, seven,
and eight items respectively. The questionnaire has 20
items in total. The scale has good internal consistency
(Cronbach’s α > .70) [39]. This measure will be entered
as a moderator on the primary outcome within the de-
finitive trial, in line with recent research findings that
PWD is more effective for those low in alexithymia [24].
We will collect the participants’ demographic informa-
tion. As part of this, we will collect data on the number
of sick days (i.e. days when unable to work or complete
usual daily activities because of health) and GP visits
that participants have experienced at each time point.
This data can then be used to measure healthcare util-
isation. We will measure quality of life using the ED-5D-
5L health questionnaire [40]. This measure has five
items and one visual analogue scale. An index score can
also be computed for use within health economics. The
measure has strong internal consistency (Cronbach’s
α = .85) [41].
For participants that are allocated to one of the writing
conditions (either PWD or WC), we will ask participants
to note down the time they start and finish writing each
day so that we can determine whether participants ad-
hered to the writing task instructions. Also, all writing
excerpts will be assessed using the Linguistic Inquiry
and Word Count (LIWC) [42]; this computer software
will measure the frequency of different word classes, as
well as the total number of words used. The results of
the LIWC will be used to assess the validity of our ma-
nipulation, i.e. those in the PWD condition should use
more positive emotion words than the WC group.
The primary outcome and secondary outcomes 1 to 4
will be collected at baseline (T0) and 1 (T1), 3 (T2), and
6 (T3) months post baseline. The primary comparison
across all outcomes will be PWD versus the WC. As-
sessments will be completed at a location that is con-
venient for the participant; all participants will be
offered home visits.
This study will employ a mixed-methods approach. In
addition to the quantitative measures described, all par-
ticipants who complete a writing task (either PWD or
WC groups) will be invited to complete an exit inter-
view. The interview discussion guide is based upon the
Change Interview protocol [43], with some minor modi-
fication requested by our C4C LEAP. The aim of the
interview is to understand participants’ experience of the
writing tasks and the study, as well as to identify if they
experienced any changes over the course of the study
and what these changes could be attributed to.
Data collection and storage
At T0, participants will be supported by a research as-
sistant to complete the baseline assessment—this assess-
ment will be completed at a time and location that is
convenient for the participant. At subsequent time
points (T1, T2, and T3), participants will be given the
option to complete these assessments either online, over
the phone, or on paper and return by post. The re-
searcher conducting the phone interviews will be
blinded to the participant’s group allocation. Any data
that is collected as a hard copy will be stored in a locked
filing cabinet at the sponsor’s site. All electronic data will
be kept in password protected files on a university com-
puter. Data will be anonymised wherever possible. The
trial research assistant will take responsibility for enter-
ing the data. For the secondary outcome measures, a
random sub-sample of 10% of the participants will have
their data checked against the Case Report Forms
(CRFs) by an independent researcher to assess the reli-
ability and quality of the data entry. For the primary
outcome, 100% of the data will be checked. Any dis-
crepancies will be investigated by the research team.
CMH will act as the data custodian and supervise all
aspects of the data collection, storage, and entry. All
data collection and storage will adhere to the Data
Protection Act (1998).
Hazell et al. Pilot and Feasibility Studies  (2017) 3:63 Page 5 of 8
Planned analysis
The data analysis will be conducted by the trial statisti-
cian (SB). The findings of this trial will be reported in
line with the CONSORT guidelines for pilot RCTs, in-
cluding a PRISMA diagram as in Fig. 1. Recruitment
rates will also be expressed as a percentage, reflecting
the number of participants who gave consent to take
part in this study relative to the total number of people
who were approached to participate. Participant reten-
tion in the study at each of the assessment time points
will be reported as a percentage. Wherever possible, the
reason for study and intervention dropout will be recor-
ded—this may not be possible for all cases where partici-
pants dropout from the study, as each participant
reserves the right to withdraw from the study without
giving any reason.
Adherence to the writing tasks (only relevant for the
PWD and WC groups) will be determined by the num-
ber of writing extracts completed (should be 3), the self-
reported times that participants started and finished
writing (should amount to 20 min per day), and the re-
sults of the Linguistic Inquiry and Word Count (LIWC)
software [42]. Comparison of the LIWC data should
show that those in the PWD group and the WC group
write similar numbers of words over the 3 days but that
the trend will be for the PWD group to use more posi-
tive words than the WC.
As this is a pilot study, analyses will be descriptive,
and statistical comparison between groups will not be
made, but rather, data for each group will be presented
separately in a table side by side, with 95% confidence
intervals [44]. The amount of complete data for the pri-
mary outcome across all time points will be expressed as
a percentage.
To our knowledge, there is no recommended Min-
imal Clinically Important Difference (MCID) for our
primary outcome, the PANAS [30]. Therefore, one of
the aims of this study is to suggest an MCID for use
in future studies. This estimation will be based on the
guidance of Copay et al. [45]: as the MCID is as-
sumed to reflect a small effect size, the baseline
standard deviation across the whole sample will be
multiplied by 0.2 (this value represents a small effect
size, as recommended by Cohen [46]).
The exit interviews with participants in the PWD and
WC groups will be transcribed, removing all identifiable
information. Where necessary, pseudonyms will be used.
The transcripts from each interview will be analysed
within QSR NVivo 11, using thematic analysis (TA) [47].
The analysis will involve research team members and
the C4C LEAP. Once familiar with the content of the
transcripts, we will generate initial codes that stay close
to the data. These codes will be semantically clustered
into sub-themes, and finally, these sub-themes will be
clustered into main themes. The final thematic structure
will be described and supported with illustrative quotes
from the interviews. The use of TA will enable us to
identify patterns of meaning within and across partici-
pants. If a definitive trial is justified, these qualitative re-
sults will be instrumental in refining the study protocol.
A definitive trial will be justified if (1) the primary
outcome measure is at least 80% complete, (2) attri-
tion is no greater than 40% by T3, and (3) the trial
and intervention are considered acceptable and ac-
cessible by patients.
Public and patient involvement (PPI)
PPI has featured in every step of the research process.
The research team has consulted caregivers using
one-to-one interviews and focus groups to clarify the
study aims and rationale. These consultations con-
firmed the absence of support for caregivers and their
enthusiasm for writing as a potential intervention.
Caregivers reported that writing interventions, like
Positive Written Disclosure, could be beneficial as
they address: (1) caregivers’ limited opportunities to
express themselves, (2) limited availability and ability
to physically attend carer support groups, and (3) the
increased burden that can come from providing peer
support within carer support groups.
The C4C LEAP has also been involved in designing
this study. Specifically, they identified alternative ap-
proaches to recruitment (e.g. involving more third sector
organisations), assisted in selecting the trial outcome
measures, and selected the images that will be used in
the WC group. Most significantly, the C4C LEAP identi-
fied that the act of writing, irrespective of the topic,
could be therapeutic—and they subsequently proposed
the inclusion of the NWC group. All of the study mate-
rials were reviewed by the C4C LEAP to ensure they
were clear and accessible. The involvement of the McPin
Foundation, a specialist mental health research charity
that champions expertise from experience in studies, has
also supported the structural development of PPI within
the study.
The C4C LEAP will continue to be part of the study.
Their role will be to monitor and advise on recruitment
(including problem solving), support qualitative data
analysis, and assist in the interpretation of the study re-
sults. At the point of dissemination, they will be involved
in planning activities.
Research governance
We have produced this protocol in line with the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines [48] (see Additional files 1, 2
and 3). This study is funded by the Dunhill Medical
Trust (R431/0715) and sponsored by the University of
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Sussex (BSMS/16/010/JON). Local governance approval
was granted by Sussex Partnership NHS Foundation
Trust. Ethical approval was granted by the North-West
Lancaster Research Ethics Committee on 24/11/2016
(REC reference: 16/NW/0757).
This pilot trial will be monitored by a Trial Steering
Committee, with an independent chair, and including
academic, clinical, trial management, and lived experi-
ence experts, in accordance with the Medical Research
Council (MRC) [49] guidelines. The trial will also be
monitored by a separate Lived Experience Advisory
Panel (C4C LEAP).
Adverse events and issues of risk will be addressed in
line with the National Institute for Health Research
Good Clinical Practice guidelines. If any adverse events
occurring during the study are deemed to be severe and
related to the study, then this may result in the early ter-
mination of the trial—this decision will be made by the
study sponsors and Trial Steering Committee. All ad-
verse events, whether they are related to the study or
not, will be reported in the final study report.
Dissemination
We plan to disseminate the results of this study to both
academic and non-academic communities. The results
will be written up for publication in a peer-reviewed aca-
demic journal, using open access routes wherever possible.
Additionally, all participants that request one will receive
a lay summary of the study findings. We also plan to dis-
seminate the findings via relevant third sector organisa-
tions, events, and publications, such as carers’ centres,
Rethink Mental Illness, and the McPin Foundation.
Discussion
The results of this pilot RCT will determine whether
Positive Written Disclosure is an acceptable intervention
for older adult caregivers of people experiencing psych-
osis symptoms. The exit interviews, recruitment and re-
tention rates, and the effect sizes of the co-primary and
secondary outcomes will all be used to determine
whether a definitive trial of PWD in this population is
justified and feasible. If the results of this trial are prom-
ising then, with the support of the C4C LEAP, the quali-
tative and quantitative results can be used to refine the
intervention and study protocols.
If PWD is found to be effective within a definitive
trial, then this intervention has the potential to im-
prove the wellbeing of a group of people currently
neglected by healthcare services. Furthermore, the
self-directed nature of PWD would mean this inter-
vention could be implemented without incurring any
significant healthcare costs.
Trial status: The trial opened for recruitment in
January 2017.
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